APO Research
Talk to an analyst

APO RESEARCH · REPORT

Kidney Transplant Rejection Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Kidney Transplant Rejection Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchKidney Transplant Rejection Therapeutics Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Kidney Transplant Rejection Therapeutics Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Kidney Transplant Rejection Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Kidney Transplant Rejection Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Kidney Transplant Rejection Therapeutics Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Kidney Transplant Rejection Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Kidney Transplant Rejection Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Kidney Transplant Rejection Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Kidney Transplant Rejection Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Kidney Transplant Rejection Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Kidney Transplant Rejection Therapeutics market include Novartis AG, GlaxoSmithKline Plc, Pharming Group N.V., Pharmicell, OSE Immunotherapeutics, Opsona Therapeutics Limited, Noorik Biopharmaceuticals AG, Magnus Life Ltd and Mabtech Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Kidney Transplant Rejection Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Kidney Transplant Rejection Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Kidney Transplant Rejection Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Kidney Transplant Rejection Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Kidney Transplant Rejection Therapeutics Segment by Company

Novartis AG

GlaxoSmithKline Plc

Pharming Group N.V.

Pharmicell

OSE Immunotherapeutics

Opsona Therapeutics Limited

Noorik Biopharmaceuticals AG

Magnus Life Ltd

Mabtech Limited

Kyowa Hakko Kirin

Hansa Medical AB

Grifols, S.A.

Digna Biotech, S.L.

CSL Limited

Kidney Transplant Rejection Therapeutics Segment by Type

Cortina

Azathioprine

Cyclophosphamide

Cyclosporin A

Other

Kidney Transplant Rejection Therapeutics Segment by Application

Clinic

Hospital

ASCs

Others

Kidney Transplant Rejection Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Kidney Transplant Rejection Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Kidney Transplant Rejection Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Kidney Transplant Rejection Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Kidney Transplant Rejection Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Transplant Rejection Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Kidney Transplant Rejection Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Transplant Rejection Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Kidney Transplant Rejection Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Kidney Transplant Rejection Therapeutics industry.

Chapter 3: Detailed analysis of Kidney Transplant Rejection Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Kidney Transplant Rejection Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Kidney Transplant Rejection Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Kidney Transplant Rejection Therapeutics Industry Trends Table 2. Kidney Transplant Rejection Therapeutics Industry Drivers Table 3. Kidney Transplant Rejection Therapeutics Industry Opportunities and Challenges Table 4. Kidney Transplant Rejection Therapeutics Industry Restraints Table 5. Global Kidney Transplant Rejection Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Kidney Transplant Rejection Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Kidney Transplant Rejection Therapeutics Sales Volume by Company (k units) & (2021-2026) Table 8. Global Kidney Transplant Rejection Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Kidney Transplant Rejection Therapeutics Average Price (US$/unit) of Company (2021-2026) Table 10. Global Kidney Transplant Rejection Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Kidney Transplant Rejection Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Kidney Transplant Rejection Therapeutics Company, Product Type & Application Table 13. Global Kidney Transplant Rejection Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Kidney Transplant Rejection Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cortina Table 18. Significant Companies of Azathioprine Table 19. Significant Companies of Cyclophosphamide Table 20. Significant Companies of Cyclosporin A Table 21. Significant Companies of Other Table 22. Global Kidney Transplant Rejection Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Kidney Transplant Rejection Therapeutics Sales Volume by Type (2021-2026) & (k units) Table 24. Global Kidney Transplant Rejection Therapeutics Sales Volume by Type (2027-2032) & (k units) Table 25. Global Kidney Transplant Rejection Therapeutics Sales Volume Share by Type (2021-2026) Table 26. Global Kidney Transplant Rejection Therapeutics Sales Volume Share by Type (2027-2032) Table 27. Global Kidney Transplant Rejection Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Kidney Transplant Rejection Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Kidney Transplant Rejection Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Kidney Transplant Rejection Therapeutics Sales Value Share by Type (2021-2026) Table 31. Global Kidney Transplant Rejection Therapeutics Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Clinic Table 33. Significant Companies of Hospital Table 34. Significant Companies of ASCs Table 35. Significant Companies of Others Table 36. Global Kidney Transplant Rejection Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Kidney Transplant Rejection Therapeutics Sales Volume by Application (2021-2026) & (k units) Table 38. Global Kidney Transplant Rejection Therapeutics Sales Volume by Application (2027-2032) & (k units) Table 39. Global Kidney Transplant Rejection Therapeutics Sales Volume Share by Application (2021-2026) Table 40. Global Kidney Transplant Rejection Therapeutics Sales Volume Share by Application (2027-2032) Table 41. Global Kidney Transplant Rejection Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Kidney Transplant Rejection Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Kidney Transplant Rejection Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Kidney Transplant Rejection Therapeutics Sales Value Share by Application (2021-2026) Table 45. Global Kidney Transplant Rejection Therapeutics Sales Value Share by Application (2027-2032) Table 46. Global Kidney Transplant Rejection Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Kidney Transplant Rejection Therapeutics Sales by Region (2021-2026) & (k units) Table 48. Global Kidney Transplant Rejection Therapeutics Sales Market Share by Region (2021-2026) Table 49. Global Kidney Transplant Rejection Therapeutics Sales by Region (2027-2032) & (k units) Table 50. Global Kidney Transplant Rejection Therapeutics Sales Market Share by Region (2027-2032) Table 51. Global Kidney Transplant Rejection Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Kidney Transplant Rejection Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Kidney Transplant Rejection Therapeutics Sales Value Share by Region (2021-2026) Table 54. Global Kidney Transplant Rejection Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Kidney Transplant Rejection Therapeutics Sales Value Share by Region (2027-2032) Table 56. Global Kidney Transplant Rejection Therapeutics Market Average Price (US$/unit) by Region (2021-2026) Table 57. Global Kidney Transplant Rejection Therapeutics Market Average Price (US$/unit) by Region (2027-2032) Table 58. Global Kidney Transplant Rejection Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Global Kidney Transplant Rejection Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Kidney Transplant Rejection Therapeutics Sales by Country (2021-2026) & (k units) Table 61. Global Kidney Transplant Rejection Therapeutics Sales Market Share by Country (2021-2026) Table 62. Global Kidney Transplant Rejection Therapeutics Sales by Country (2027-2032) & (k units) Table 63. Global Kidney Transplant Rejection Therapeutics Sales Market Share by Country (2027-2032) Table 64. Global Kidney Transplant Rejection Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Kidney Transplant Rejection Therapeutics Sales Value Market Share by Country (2021-2026) Table 66. Global Kidney Transplant Rejection Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Kidney Transplant Rejection Therapeutics Sales Value Market Share by Country (2027-2032) Table 68. Novartis AG Company Information Table 69. Novartis AG Business Overview Table 70. Novartis AG Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Novartis AG Kidney Transplant Rejection Therapeutics Product Portfolio Table 72. Novartis AG Recent Development Table 73. GlaxoSmithKline Plc Company Information Table 74. GlaxoSmithKline Plc Business Overview Table 75. GlaxoSmithKline Plc Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. GlaxoSmithKline Plc Kidney Transplant Rejection Therapeutics Product Portfolio Table 77. GlaxoSmithKline Plc Recent Development Table 78. Pharming Group N.V. Company Information Table 79. Pharming Group N.V. Business Overview Table 80. Pharming Group N.V. Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Pharming Group N.V. Kidney Transplant Rejection Therapeutics Product Portfolio Table 82. Pharming Group N.V. Recent Development Table 83. Pharmicell Company Information Table 84. Pharmicell Business Overview Table 85. Pharmicell Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Pharmicell Kidney Transplant Rejection Therapeutics Product Portfolio Table 87. Pharmicell Recent Development Table 88. OSE Immunotherapeutics Company Information Table 89. OSE Immunotherapeutics Business Overview Table 90. OSE Immunotherapeutics Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. OSE Immunotherapeutics Kidney Transplant Rejection Therapeutics Product Portfolio Table 92. OSE Immunotherapeutics Recent Development Table 93. Opsona Therapeutics Limited Company Information Table 94. Opsona Therapeutics Limited Business Overview Table 95. Opsona Therapeutics Limited Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Opsona Therapeutics Limited Kidney Transplant Rejection Therapeutics Product Portfolio Table 97. Opsona Therapeutics Limited Recent Development Table 98. Noorik Biopharmaceuticals AG Company Information Table 99. Noorik Biopharmaceuticals AG Business Overview Table 100. Noorik Biopharmaceuticals AG Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Noorik Biopharmaceuticals AG Kidney Transplant Rejection Therapeutics Product Portfolio Table 102. Noorik Biopharmaceuticals AG Recent Development Table 103. Magnus Life Ltd Company Information Table 104. Magnus Life Ltd Business Overview Table 105. Magnus Life Ltd Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Magnus Life Ltd Kidney Transplant Rejection Therapeutics Product Portfolio Table 107. Magnus Life Ltd Recent Development Table 108. Mabtech Limited Company Information Table 109. Mabtech Limited Business Overview Table 110. Mabtech Limited Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Mabtech Limited Kidney Transplant Rejection Therapeutics Product Portfolio Table 112. Mabtech Limited Recent Development Table 113. Kyowa Hakko Kirin Company Information Table 114. Kyowa Hakko Kirin Business Overview Table 115. Kyowa Hakko Kirin Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Kyowa Hakko Kirin Kidney Transplant Rejection Therapeutics Product Portfolio Table 117. Kyowa Hakko Kirin Recent Development Table 118. Hansa Medical AB Company Information Table 119. Hansa Medical AB Business Overview Table 120. Hansa Medical AB Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Hansa Medical AB Kidney Transplant Rejection Therapeutics Product Portfolio Table 122. Hansa Medical AB Recent Development Table 123. Grifols, S.A. Company Information Table 124. Grifols, S.A. Business Overview Table 125. Grifols, S.A. Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Grifols, S.A. Kidney Transplant Rejection Therapeutics Product Portfolio Table 127. Grifols, S.A. Recent Development Table 128. Digna Biotech, S.L. Company Information Table 129. Digna Biotech, S.L. Business Overview Table 130. Digna Biotech, S.L. Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Digna Biotech, S.L. Kidney Transplant Rejection Therapeutics Product Portfolio Table 132. Digna Biotech, S.L. Recent Development Table 133. CSL Limited Company Information Table 134. CSL Limited Business Overview Table 135. CSL Limited Kidney Transplant Rejection Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. CSL Limited Kidney Transplant Rejection Therapeutics Product Portfolio Table 137. CSL Limited Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Kidney Transplant Rejection Therapeutics Distributors List Table 141. Kidney Transplant Rejection Therapeutics Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Kidney Transplant Rejection Therapeutics Product Image Figure 2. Global Kidney Transplant Rejection Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Kidney Transplant Rejection Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Kidney Transplant Rejection Therapeutics Sales (2021-2032) & (k units) Figure 5. Global Kidney Transplant Rejection Therapeutics Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Kidney Transplant Rejection Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cortina Image Figure 10. Azathioprine Image Figure 11. Cyclophosphamide Image Figure 12. Cyclosporin A Image Figure 13. Other Image Figure 14. Global Kidney Transplant Rejection Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Kidney Transplant Rejection Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Kidney Transplant Rejection Therapeutics Sales Volume Share by Type (2021-2032) Figure 17. Global Kidney Transplant Rejection Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Kidney Transplant Rejection Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Kidney Transplant Rejection Therapeutics Sales Value Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. ASCs Image Figure 23. Others Image Figure 24. Global Kidney Transplant Rejection Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Kidney Transplant Rejection Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Kidney Transplant Rejection Therapeutics Sales Volume Share by Application (2021-2032) Figure 27. Global Kidney Transplant Rejection Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Kidney Transplant Rejection Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Kidney Transplant Rejection Therapeutics Sales Value Share by Application (2021-2032) Figure 30. Global Kidney Transplant Rejection Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 31. Global Kidney Transplant Rejection Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Kidney Transplant Rejection Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Kidney Transplant Rejection Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Kidney Transplant Rejection Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 35. North America Kidney Transplant Rejection Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Kidney Transplant Rejection Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Kidney Transplant Rejection Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Kidney Transplant Rejection Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Kidney Transplant Rejection Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Kidney Transplant Rejection Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 41. South America Kidney Transplant Rejection Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Kidney Transplant Rejection Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Kidney Transplant Rejection Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Kidney Transplant Rejection Therapeutics Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Kidney Transplant Rejection Therapeutics Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Cortina
  • Azathioprine
  • Cyclophosphamide
  • Cyclosporin A
  • Other
Applications
  • Clinic
  • Hospital
  • ASCs
  • Others
Companies covered
  • Novartis AG
  • GlaxoSmithKline Plc
  • Pharming Group N.V.
  • Pharmicell
  • OSE Immunotherapeutics
  • Opsona Therapeutics Limited
  • Noorik Biopharmaceuticals AG
  • Magnus Life Ltd
  • Mabtech Limited
  • Kyowa Hakko Kirin
  • Hansa Medical AB
  • Grifols, S.A.
  • Digna Biotech, S.L.
  • CSL Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Kidney Transplant Rejection Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Kidney Transplant Rejection Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Kidney Transplant Rejection Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Kidney Transplant Rejection Therapeutics Market Dynamics
  1. 2.1 Kidney Transplant Rejection Therapeutics Industry Trends
  2. 2.2 Kidney Transplant Rejection Therapeutics Industry Drivers
  3. 2.3 Kidney Transplant Rejection Therapeutics Industry Opportunities and Challenges
  4. 2.4 Kidney Transplant Rejection Therapeutics Industry Restraints
3 Kidney Transplant Rejection Therapeutics Market by Company
  1. 3.1 Global Kidney Transplant Rejection Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Kidney Transplant Rejection Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Kidney Transplant Rejection Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Kidney Transplant Rejection Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Kidney Transplant Rejection Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Kidney Transplant Rejection Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Kidney Transplant Rejection Therapeutics Company Product Type and Application
  8. 3.8 Global Kidney Transplant Rejection Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Kidney Transplant Rejection Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Kidney Transplant Rejection Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Kidney Transplant Rejection Therapeutics Market by Type
  1. 4.1 Kidney Transplant Rejection Therapeutics Type Introduction
  2. 4.1.1 Cortina
  3. 4.1.2 Azathioprine
  4. 4.1.3 Cyclophosphamide
  5. 4.1.4 Cyclosporin A
  6. 4.1.5 Other
  7. 4.2 Global Kidney Transplant Rejection Therapeutics Sales Volume by Type
  8. 4.2.1 Global Kidney Transplant Rejection Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Kidney Transplant Rejection Therapeutics Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Kidney Transplant Rejection Therapeutics Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Kidney Transplant Rejection Therapeutics Sales Value by Type
  12. 4.3.1 Global Kidney Transplant Rejection Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Kidney Transplant Rejection Therapeutics Sales Value by Type (2021-2032)
  14. 4.3.3 Global Kidney Transplant Rejection Therapeutics Sales Value Share by Type (2021-2032)
5 Kidney Transplant Rejection Therapeutics Market by Application
  1. 5.1 Kidney Transplant Rejection Therapeutics Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 ASCs
  5. 5.1.4 Others
  6. 5.2 Global Kidney Transplant Rejection Therapeutics Sales Volume by Application
  7. 5.2.1 Global Kidney Transplant Rejection Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Kidney Transplant Rejection Therapeutics Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Kidney Transplant Rejection Therapeutics Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Kidney Transplant Rejection Therapeutics Sales Value by Application
  11. 5.3.1 Global Kidney Transplant Rejection Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Kidney Transplant Rejection Therapeutics Sales Value by Application (2021-2032)
  13. 5.3.3 Global Kidney Transplant Rejection Therapeutics Sales Value Share by Application (2021-2032)
6 Kidney Transplant Rejection Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Kidney Transplant Rejection Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Kidney Transplant Rejection Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Kidney Transplant Rejection Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Kidney Transplant Rejection Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Kidney Transplant Rejection Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Kidney Transplant Rejection Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Kidney Transplant Rejection Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Kidney Transplant Rejection Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Kidney Transplant Rejection Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Kidney Transplant Rejection Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Kidney Transplant Rejection Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Kidney Transplant Rejection Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Kidney Transplant Rejection Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Kidney Transplant Rejection Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Kidney Transplant Rejection Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Kidney Transplant Rejection Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Kidney Transplant Rejection Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Kidney Transplant Rejection Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Kidney Transplant Rejection Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Kidney Transplant Rejection Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Kidney Transplant Rejection Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Kidney Transplant Rejection Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Kidney Transplant Rejection Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Kidney Transplant Rejection Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Kidney Transplant Rejection Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Kidney Transplant Rejection Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Kidney Transplant Rejection Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Kidney Transplant Rejection Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Kidney Transplant Rejection Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Kidney Transplant Rejection Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Kidney Transplant Rejection Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Kidney Transplant Rejection Therapeutics Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Kidney Transplant Rejection Therapeutics Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 Pharming Group N.V.
  14. 8.3.1 Pharming Group N.V. Company Information
  15. 8.3.2 Pharming Group N.V. Business Overview
  16. 8.3.3 Pharming Group N.V. Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pharming Group N.V. Kidney Transplant Rejection Therapeutics Product Portfolio
  18. 8.3.5 Pharming Group N.V. Recent Developments
  19. 8.4 Pharmicell
  20. 8.4.1 Pharmicell Company Information
  21. 8.4.2 Pharmicell Business Overview
  22. 8.4.3 Pharmicell Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pharmicell Kidney Transplant Rejection Therapeutics Product Portfolio
  24. 8.4.5 Pharmicell Recent Developments
  25. 8.5 OSE Immunotherapeutics
  26. 8.5.1 OSE Immunotherapeutics Company Information
  27. 8.5.2 OSE Immunotherapeutics Business Overview
  28. 8.5.3 OSE Immunotherapeutics Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 OSE Immunotherapeutics Kidney Transplant Rejection Therapeutics Product Portfolio
  30. 8.5.5 OSE Immunotherapeutics Recent Developments
  31. 8.6 Opsona Therapeutics Limited
  32. 8.6.1 Opsona Therapeutics Limited Company Information
  33. 8.6.2 Opsona Therapeutics Limited Business Overview
  34. 8.6.3 Opsona Therapeutics Limited Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Opsona Therapeutics Limited Kidney Transplant Rejection Therapeutics Product Portfolio
  36. 8.6.5 Opsona Therapeutics Limited Recent Developments
  37. 8.7 Noorik Biopharmaceuticals AG
  38. 8.7.1 Noorik Biopharmaceuticals AG Company Information
  39. 8.7.2 Noorik Biopharmaceuticals AG Business Overview
  40. 8.7.3 Noorik Biopharmaceuticals AG Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Noorik Biopharmaceuticals AG Kidney Transplant Rejection Therapeutics Product Portfolio
  42. 8.7.5 Noorik Biopharmaceuticals AG Recent Developments
  43. 8.8 Magnus Life Ltd
  44. 8.8.1 Magnus Life Ltd Company Information
  45. 8.8.2 Magnus Life Ltd Business Overview
  46. 8.8.3 Magnus Life Ltd Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Magnus Life Ltd Kidney Transplant Rejection Therapeutics Product Portfolio
  48. 8.8.5 Magnus Life Ltd Recent Developments
  49. 8.9 Mabtech Limited
  50. 8.9.1 Mabtech Limited Company Information
  51. 8.9.2 Mabtech Limited Business Overview
  52. 8.9.3 Mabtech Limited Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mabtech Limited Kidney Transplant Rejection Therapeutics Product Portfolio
  54. 8.9.5 Mabtech Limited Recent Developments
  55. 8.10 Kyowa Hakko Kirin
  56. 8.10.1 Kyowa Hakko Kirin Company Information
  57. 8.10.2 Kyowa Hakko Kirin Business Overview
  58. 8.10.3 Kyowa Hakko Kirin Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Kyowa Hakko Kirin Kidney Transplant Rejection Therapeutics Product Portfolio
  60. 8.10.5 Kyowa Hakko Kirin Recent Developments
  61. 8.11 Hansa Medical AB
  62. 8.11.1 Hansa Medical AB Company Information
  63. 8.11.2 Hansa Medical AB Business Overview
  64. 8.11.3 Hansa Medical AB Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hansa Medical AB Kidney Transplant Rejection Therapeutics Product Portfolio
  66. 8.11.5 Hansa Medical AB Recent Developments
  67. 8.12 Grifols, S.A.
  68. 8.12.1 Grifols, S.A. Company Information
  69. 8.12.2 Grifols, S.A. Business Overview
  70. 8.12.3 Grifols, S.A. Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Grifols, S.A. Kidney Transplant Rejection Therapeutics Product Portfolio
  72. 8.12.5 Grifols, S.A. Recent Developments
  73. 8.13 Digna Biotech, S.L.
  74. 8.13.1 Digna Biotech, S.L. Company Information
  75. 8.13.2 Digna Biotech, S.L. Business Overview
  76. 8.13.3 Digna Biotech, S.L. Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Digna Biotech, S.L. Kidney Transplant Rejection Therapeutics Product Portfolio
  78. 8.13.5 Digna Biotech, S.L. Recent Developments
  79. 8.14 CSL Limited
  80. 8.14.1 CSL Limited Company Information
  81. 8.14.2 CSL Limited Business Overview
  82. 8.14.3 CSL Limited Kidney Transplant Rejection Therapeutics Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 CSL Limited Kidney Transplant Rejection Therapeutics Product Portfolio
  84. 8.14.5 CSL Limited Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Kidney Transplant Rejection Therapeutics Value Chain Analysis
  2. 9.1.1 Kidney Transplant Rejection Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Kidney Transplant Rejection Therapeutics Sales Mode & Process
  6. 9.2 Kidney Transplant Rejection Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Kidney Transplant Rejection Therapeutics Distributors
  9. 9.2.3 Kidney Transplant Rejection Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst